Biocon has dipped 4% to Rs 278 after reporting 21% year-on-year (yoy) drop in its consolidated operating profit at Rs 124 crore for the quarter ended March 2013 (Q4) due to higher material, power and staff cost.
The company’s operating or EBIDTA margin contracted by 540bp to 19.68% from 25.08% during the recently concluded quarter.
Meanwhile, the biotechnology company has posted a net profit of Rs 249 crore for the quarter mainly due to an exceptional income of Rs 202 crore.
Biocon during the past quarter received a $20 million one-time inflow from one of its partners - Mylan, as both the companies expanded the scope of partnership to incorporate generic insulin analogs.
The company’s total sales grew 7% at Rs 630 crore on yoy basis, while manufacturing, staff and other expenses increased by 13% to Rs 525 crore over the previous year.
The stock opened at Rs 287 and hit a low of Rs 277 on NSE. A combined 687,290 shares have changed hands on the counter till 1215 hours on NSE and BSE.
The company’s operating or EBIDTA margin contracted by 540bp to 19.68% from 25.08% during the recently concluded quarter.
Meanwhile, the biotechnology company has posted a net profit of Rs 249 crore for the quarter mainly due to an exceptional income of Rs 202 crore.
Biocon during the past quarter received a $20 million one-time inflow from one of its partners - Mylan, as both the companies expanded the scope of partnership to incorporate generic insulin analogs.
The company’s total sales grew 7% at Rs 630 crore on yoy basis, while manufacturing, staff and other expenses increased by 13% to Rs 525 crore over the previous year.
The stock opened at Rs 287 and hit a low of Rs 277 on NSE. A combined 687,290 shares have changed hands on the counter till 1215 hours on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%